Navigation Links
Getting to the roots of hair loss
Date:2/24/2008

A healthy individual loses around a hundred hairs a day. Nothing to worry about as long as they are constantly replaced and the losses occur evenly around the whole scalp. But when hair loss goes well beyond this level it can become quite a problem for those affected not only superficially in terms of looks but also psychologically. A breakthrough on the hair front has now been made by an international research team headed by scientists at the University of Bonn. After six years of research they have succeeded in identifying a gene that is responsible for a rare hereditary form of hair loss known as Hypotrichosis simplex. The scientists are the first to identify a receptor that plays a role in hair growth. They now hope that their research findings will lead to new therapies that will work with various forms of hair loss. The study, due to appear in the March edition of "Nature Genetics", can be accessed in advance on the internet (http://dx.doi.org/10.1038/ng.84) from January 24 (1pm US Eastern Time).

"Although Hypotrichosis simplex is very uncommon, it may prove critical in our search for an understand of the mechanisms of hair growth," says project leader Dr. Regina Betz from Bonn's Institute of Human Genetics, summing up the research results. The disease is inherited and affects both men and women. Sufferers generally begin to go bald during childhood. The process of hair loss (alopecia) then advances with age, especially around the scalp.

The cause of Hypotrichosis simplex in the form examined in this project is a genetic defect. It prevents certain receptor structures on the surface of hair follicle cells from being correctly formed. It has been found that when messengers from outside bind to these receptors they trigger a chain reaction in the cell interior which is apparently needed for the hair follicle to function normally. Such a receptor that plays a specific role in hair growth was pr
'/>"/>

Contact: Dr. Regina C. Betz
regina.betz@uni-bonn.de
49-228-287-22344
University of Bonn
Source:Eurekalert

Page: 1 2

Related medicine news :

1. Pay-For-Performance Not Getting a Red-Carpet Reception in Arizona
2. Chemical Linked to Reproductive Harm Is Getting Into Babies From Shampoo, Lotion and Powder, New Study Suggests
3. Acne And Rosacea Getting You Down? Laser, Light And Cosmetic Treatments Give Patients A Much-Needed Boost
4. NFL Linemen Predisposed to Cardiovascular Disease; Early Detection is Key to Getting and Staying Healthy
5. ER Wait Times Getting Longer
6. Teens getting help for suicidal behavior from an online community
7. New meal planning website launches just in time to help todays busy, health-conscious families and individuals to beat the odds when it comes to keeping their New Years resolutions around eating healthier and getting organized
8. ICU Patients Not Getting Enough Sleep
9. If You Are 50 and Over, Make Getting Screened for Colorectal Cancer Your New Years Resolution
10. AUDIO from Medialink and Philips: Getting Rid of the Uninvited Holiday Guests on Your Toothbrush
11. Fewer Women Getting Mammograms
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2008)... Though the number of jobs created i... companies reported a different kind of slowdown: ...s months. , Seattle, WA (...created in the medical field slowed in June overal...ind of slowdown that will be music to the ears of ...
(Date:7/25/2008)... supporting the US Department of Defense and Feder... Phoenix. Operation Golden Phoenix is a, four-da...ned to assist, federal, state and local agencies w...os. Dataline is providing a vital, ad-hoc, secure ... use during the exercise., NORFOLK, Va., July 25 ...
(Date:7/25/2008)...elationship Based on Significant Improvements in M...MDdatacor, Inc., a leader in health,care quality m..., today,announced it has entered into a long-term ...rt Wellmark,s Collaboration on Quality(SM) Incent ...ion between Wellmark and,primary care clinicians t...
(Date:7/25/2008)...URG, Ill., July 25 /PRNewswire/ -- Sagent Pharmace...utical company, today announced that it,has launch...arrhythmic,indicated for the treatment and prophyl...ion and hemodynamically unstable ventricular,tachy... heart beat.,Sagent,s amiodarone HCl injection wil...
Breaking Medicine News(10 mins):Health News:The MedZilla Report: June 2008 Employment Outlook for Biotech/Pharma/Health 2Health News:The MedZilla Report: June 2008 Employment Outlook for Biotech/Pharma/Health 3Health News:Dataline Announces Participation in Operation Golden Phoenix 2Health News:Dataline Announces Participation in Operation Golden Phoenix 3Health News:MDdatacor Extends Contract with Wellmark, Inc. 2Health News:MDdatacor Extends Contract with Wellmark, Inc. 3Health News:Sagent Pharmaceuticals Launches Amiodarone HCl Injection, USP 2Health News:Sagent Pharmaceuticals Launches Amiodarone HCl Injection, USP 3
...s of energy loss during aerobic exercises and this...w our bodies react to exercise programs is genetic...cising like the level of blood glucose in the body...publishing the works of scientists from Washington...
...dies, a part of the Zydus group, has launched Flud...onic lymphocytic leukemia. Chronic Lymphocytic Leu...a serious, progressive disease, which at present h...very uncommon in young people and becomes progress...
...s that the smokers may differ in their cravings// ... to smoking. Researchers have found that the urge ... smokers according to the brain responses to the s...e University Medical Center had looked into the br...
...nts to produce vaccines and other treatments for m...nd they hope to start clinical trials by the year ...will be of greatest benefit to developing nations ...very poor at the same time keeping in mind that hu...
Other Medicine News:Health News:Producing Vaccines from genetically modified crops 2
(Date:7/22/2008)...pment Initiative bring MJFF,s,current active indus...,2009, NEW YORK, July 22 /PRNewswire-USNewswire/...ansformative treatments and a cure for Parkinson,s...son,s Research has awarded,$2.7 million in total f...were granted under MJFF,s Therapeutics Development...
(Date:7/22/2008)...acy of Treating Patients with ...GIN-SI, South Korea, July 22 /-,Jenne... and its South,Korean partner Green Cross Corp., a...clinical trial of its first-in-class lead product ...rated and resulted in clear,anti-cancer efficacy i...
(Date:7/22/2008)...dra(R) Resulted in Significant, Reductions in A1C ...orithm Used, BRI...om the "Adjust to,Target in Type 2 Diabetes: Compa...ng for Adjustment of Mealtime Insulin Glulisine" s...ciation,s (ADA) medical journal,Diabetes Care. Th...
(Date:7/22/2008)...RNewswire/ -- Hyperion,Therapeutics, Inc. today an...n its Phase 1/2 clinical trial to evaluate the saf...f HPN-100 (formally called GT4P) versus,BUPHENYL(R...cle disorders,(UCD). The company plans to announce...ar., (Logo: http://www.newscom.com/cgi-bin/prnh/...
Breaking Medicine Technology:Michael J. Fox Foundation Awards $2.7 Million for Industry Efforts to Speed New Parkinson's Therapeutics 2Michael J. Fox Foundation Awards $2.7 Million for Industry Efforts to Speed New Parkinson's Therapeutics 3Jennerex Publishes Clinical Trial Data With Lead Product JX-594 Demonstrating Efficacy Against Liver Cancer and Associated Hepatitis B Virus 2Jennerex Publishes Clinical Trial Data With Lead Product JX-594 Demonstrating Efficacy Against Liver Cancer and Associated Hepatitis B Virus 3Jennerex Publishes Clinical Trial Data With Lead Product JX-594 Demonstrating Efficacy Against Liver Cancer and Associated Hepatitis B Virus 4Newly Published Study Results Showed That Two Mealtime Insulin Dosing Algorithms Were Effective for Patients with Type 2 Diabetes 2Newly Published Study Results Showed That Two Mealtime Insulin Dosing Algorithms Were Effective for Patients with Type 2 Diabetes 3Newly Published Study Results Showed That Two Mealtime Insulin Dosing Algorithms Were Effective for Patients with Type 2 Diabetes 4Hyperion Therapeutics Completes Enrollment in Phase 1/2 Clinical Trial in Patients With Urea Cycle Disorders 2Hyperion Therapeutics Completes Enrollment in Phase 1/2 Clinical Trial in Patients With Urea Cycle Disorders 3GenOdyssee Receives Notice of Allowance from U S Patent Office for Improved Interferon Alpha Aimed at Hepatitis C 11888 1GenOdyssee Receives Notice of Allowance from U S Patent Office for Improved Interferon Alpha Aimed at Hepatitis C 11888 2GenOdyssee Receives Notice of Allowance from U S Patent Office for Improved Interferon Alpha Aimed at Hepatitis C 11888 3St Valentines Day Wishes 3A Perfume 3F Jewelry 3F Labiaplasty 3F 11886 1St Valentines Day Wishes 3A Perfume 3F Jewelry 3F Labiaplasty 3F 11886 2Sanofi Pasteur and Statens Serum Institut Team Up Against Tuberculosis 3284 1Sanofi Pasteur and Statens Serum Institut Team Up Against Tuberculosis 3284 2Sanofi Pasteur and Statens Serum Institut Team Up Against Tuberculosis 3284 3Sanofi Pasteur and Statens Serum Institut Team Up Against Tuberculosis 3284 4Pharmaxis to Apply to Market Bronchitol in Australia 3283 1Pharmaxis to Apply to Market Bronchitol in Australia 3283 2Pharmaxis to Apply to Market Bronchitol in Australia 3283 3
...n three investigational,agents (VEGF Trap, S-1 and...SCO meeting, BRIDGEWATER, N.J., May 29, 2007 /PRNe...y that a total of 375 abstracts,indicative of its ...d Annual Meeting of the American Society of Clinic... 2007). The results from key,studies involving the...
...INNOVIVE Pharmaceuticals,Inc. (OTCBB: IVPH) today...of INNO-406, an orally bioavailable dual Bcr-Abl a...r,treatment-intolerant chronic myelogenous leukemi...of Clinical Oncology Annual,Meeting. The meeting t...hicago, Illinois., Information related to the pres...
Other Medicine Technology:Data to be Presented at ASCO 2007 Highlights sanofi-aventis,Commitment to Cancer Care and Research 2Data to be Presented at ASCO 2007 Highlights sanofi-aventis,Commitment to Cancer Care and Research 3Data to be Presented at ASCO 2007 Highlights sanofi-aventis,Commitment to Cancer Care and Research 4Data to be Presented at ASCO 2007 Highlights sanofi-aventis,Commitment to Cancer Care and Research 5Data to be Presented at ASCO 2007 Highlights sanofi-aventis,Commitment to Cancer Care and Research 6Data to be Presented at ASCO 2007 Highlights sanofi-aventis,Commitment to Cancer Care and Research 7Data to be Presented at ASCO 2007 Highlights sanofi-aventis,Commitment to Cancer Care and Research 8Data to be Presented at ASCO 2007 Highlights sanofi-aventis,Commitment to Cancer Care and Research 9Data to be Presented at ASCO 2007 Highlights sanofi-aventis,Commitment to Cancer Care and Research 10Data to be Presented at ASCO 2007 Highlights sanofi-aventis,Commitment to Cancer Care and Research 11Data to be Presented at ASCO 2007 Highlights sanofi-aventis,Commitment to Cancer Care and Research 12Innovive Pharmaceuticals to Present Interim Data from Phase I Study,of INNO-406 at the American Society of Clinical Oncology Annual,Meeting 2
...nce laboratory and a worldwide leader in innovativ... an extensive test menu of highly complex and uniq...y. Owned by the University of Utah, ARUP Laborator...s university teaching hospitals and children's hos...
...nce laboratory and a worldwide leader in innovativ... an extensive test menu of highly complex and uniq...y. Owned by the University of Utah, ARUP Laborator...s university teaching hospitals and children's hos...
...nce laboratory and a worldwide leader in innovativ... an extensive test menu of highly complex and uniq...y. Owned by the University of Utah, ARUP Laborator...s university teaching hospitals and children's hos...
...nce laboratory and a worldwide leader in innovativ... an extensive test menu of highly complex and uniq...y. Owned by the University of Utah, ARUP Laborator...s university teaching hospitals and children's hos...
Medicine Products: